Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 210

Results For "CRE"

4456 News Found

BioAsia 2024 to focus on data and AI for life sciences
News | January 11, 2024

BioAsia 2024 to focus on data and AI for life sciences

The three-day forum will feature global leaders, scientists, regulatory body representatives, industry associations, and academia among many others


Shanghai Argo announces multi-program RNAi licenses with Novartis
News | January 11, 2024

Shanghai Argo announces multi-program RNAi licenses with Novartis

Argo will receive upfront payments of US$ 185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales.


Hikal invests Rs. 500 crore into fine chemicals plant at Panoli
News | January 10, 2024

Hikal invests Rs. 500 crore into fine chemicals plant at Panoli

Signs MoU with the Govt. of Gujarat at Vibrant Gujarat Summit


Tata 1mg and Vitonnix UK get into an exclusive partnership in India
News | January 10, 2024

Tata 1mg and Vitonnix UK get into an exclusive partnership in India

Launch innovative vitamin sublingual sprays


Merck to acquire Harpoon Therapeutics for US$ 680 million
News | January 10, 2024

Merck to acquire Harpoon Therapeutics for US$ 680 million

Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors


Lupin launches second edition of Aptivate Champion Run for Kids
News | January 09, 2024

Lupin launches second edition of Aptivate Champion Run for Kids

Lupin Life encourages children from Mumbai, Thane, and Navi Mumbai to participate in Aptivate Champion Run


European Commission approves Pfizer’s Talzenna in combination with Xtandi for treatment of metastatic castration-resistant prostate cancer
Drug Approval | January 09, 2024

European Commission approves Pfizer’s Talzenna in combination with Xtandi for treatment of metastatic castration-resistant prostate cancer

TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union


Mandaviya inaugurates CDSCO Sub Zonal Office and Central Drug Testing Laboratory in Indore
News | January 08, 2024

Mandaviya inaugurates CDSCO Sub Zonal Office and Central Drug Testing Laboratory in Indore

Lays Foundation Stone of 6 new facilities at AIIMS Bhopal and inaugurates a slew of facilities in Madhya Pradesh


Omniose collaborates with AstraZeneca to research vaccines for serious bacterial diseases
Clinical Trials | January 07, 2024

Omniose collaborates with AstraZeneca to research vaccines for serious bacterial diseases

Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens


Servier and Base4 partner to advance neuroscience drug development
Clinical Trials | January 06, 2024

Servier and Base4 partner to advance neuroscience drug development

Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases